In vitro anti-Toxoplasma gondii activity of Ganoderma lucidum extracts

被引：2

作者：

Ahmadi, Mohammad ^{[1
]}

Salimi, Mahboobeh ^{[2
]}

Saraei, Mehrzad ^{[3
,4
]}

Nezhad, Niloofar Salavati ^{[5
]}

Javadi, Amir ^{[6
]}

Mohammadi, Faezeh ^{[3
,4
]}

Heydarian, Peyman ^{[3
,4
]}

Ali, Ehsan ^{[7
]}

Hajialilo, Elham ^{[3
,4
]}

机构：

[1] Qazvin Univ Med Sci, Student Res Comm, Qazvin, Iran

[2] Univ Tehran Med Sci, Dept Med Parasitol & Mycol, Tehran, Iran

[3] Qazvin Univ Med Sci, Med Microbiol Res Ctr, Qazvin, Iran

[4] Qazvin Univ Med Sci, Dept Parasitol & Mycol, Qazvin, Iran

[5] Qazvin Univ Med Sci, Fac Allied Med, Dept Med Biotechnol, Qazvin, Iran

[6] Qazvin Univ Med Sci, Sch Med, Dept Community Med, Qazvin, Iran

[7] Qazvin Univ Med Sci, Dept Pharmacol, Qazvin, Iran

来源：

BMC RESEARCH NOTES | 2023年 / 16卷 / 01期

关键词：

Toxoplasma gondii; Ganoderma lucidum; In vitro; Iran; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT; BODY;

D O I：

10.1186/s13104-023-06355-6

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

ObjectiveGanoderma extracts have the potential to be used as anti-cancer, anti-inflammatory, immunomodulator, and antimicrobial agents, as evaluated in numerous studies. This study was aimed to determine the lethal and inhibitory effects of aqueous, hydroalcoholic, and alcoholic extracts of Ganoderma lucidum on Toxoplasma gondii RH strain tachyzoites, in vitro.ResultsAll three types of extracts showed toxoplasmacidal effects. The highest percentage of mortality was related to hydroalcoholic extract. The EC50 of Ganoderma extracts for tachyzoites were 76.32, 3.274, and 40.18 for aqueous, hydroalcoholic and alcoholic extracts, respectively. The selectivity index obtained for hydroalcoholic extract was 71.22, showing the highest activity compared to other extracts. According to our findings, the hydroalcoholic part was the most effective substance among the extracts. This basic study showed obvious anti-toxoplasma effect of Ganoderma lucidum extracts. These extracts can be used as candidates for further in-depth and comprehensive studies especially In vivo experiments to prevent toxoplasmosis.

引用

页数：6

共 39 条

[1] Anti-Toxoplasma activity of Sorghum bicolor-derived lipophilic fractions
Abugri, Daniel A.
Jaynes, Jesse M.
Witola, William H.
[J]. BMC RESEARCH NOTES, 2019, 12 (01)
[2] Antiplasmodial Lanostanes from the Ganoderma lucidum Mushroom
Adams, Michael
Christen, Marco
Plitzko, Inken
Zimmermann, Stefanie
Brun, Reto
Kaiser, Marcel
Hamburger, Matthias
[J]. JOURNAL OF NATURAL PRODUCTS, 2010, 73 (05): : 897 - 900
[3] Akbari S., 2019, J ISFAHAN MED SCH, V36, P1628
[4] Akbari S, 2019, J ISFAHAN MED SCH, P36
[5] Drugs in development for toxoplasmosis: advances, challenges, and current status
Alday, P. Holland
Doggett, Joseph Stone
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 : 273 - 293
[6] Anshumali Rawat Anshumali Rawat, 2012, Advances in Applied Science Research, V3, P3708
[7] Bach Erna Elisabeth, 2018, Medicines (Basel), V5, DOI 10.3390/medicines5030078
[8] Lytic cycle of Toxoplasma gondii
Black, MW
Boothroyd, JC
[J]. MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 2000, 64 (03) : 607 - +
[9] A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis
Bosch-Driessen, LH
Verbraak, FD
Suttorp-Schulten, MSA
van Ruyven, RLJ
Klok, AM
Hoyng, CB
Rothova, A
[J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2002, 134 (01) : 34 - 40
[10] Buddha B, 2017, MYCOLOGY-UK, P8

← 1 2 3 4 →